Dasatinib API Powder: High-Purity Antineoplastic for Leukemia Treatment
Empowering advancements in oncology with high-purity Dasatinib API powder for effective leukemia therapies.
Get a Quote & SampleProduct Core Value
Dasatinib API Powder
Dasatinib API Powder is a critical anti-cancer medication, functioning as an oral tyrosine kinase inhibitor. It is instrumental in treating various forms of leukemia, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its mechanism of action involves inhibiting key kinases like BCR-ABL and SRC family kinases, thereby disrupting cancer cell signaling pathways and impeding their growth and proliferation. This high-purity powder ensures efficacy and is a vital component in the pharmaceutical industry for developing targeted cancer therapies.
- The potent tyrosine kinase inhibitor activity of Dasatinib API Powder makes it essential for targeted cancer treatments.
- With a high purity of over 99%, this Dasatinib API Powder is formulated for maximum therapeutic effectiveness in leukemia patients.
- Sourced from reliable Dasatinib Monohydrate Manufacturers, this pharmaceutical-grade powder guarantees quality and consistency.
- Utilized as a key Leukemia Treatment Medication, it offers a targeted approach to managing complex hematological malignancies.
Product Advantages
Targeted Therapy Mechanism
This Tyrosine Kinase Inhibitor API specifically targets oncogenic kinases, offering a precise treatment strategy against cancer cell replication.
High Purity and Efficacy
Ensuring over 99% purity, the Dasatinib CAS 302962-49-8 powder is manufactured to stringent pharmaceutical standards, guaranteeing optimal therapeutic outcomes.
Critical in Oncology
As a vital component in the Pharmaceutical Intermediate Supply Chain, it supports the development of advanced anti-cancer drugs, particularly for hematological disorders.
Key Applications
Leukemia Treatment
A cornerstone in treating Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL), offering hope to patients through its targeted mechanism.
Oncology Research and Development
Serves as a crucial research chemical in the development of new anti-cancer drugs and therapies, driving innovation in cancer treatment.
Pharmaceutical Manufacturing
Essential raw material for pharmaceutical companies to manufacture finished dosage forms, ensuring quality and compliance in drug production.
Targeted Cancer Therapies
Enables the development of advanced, targeted cancer therapies by inhibiting specific protein kinases involved in disease progression.